Tiplaxtinin as a PAI-1 inhibitor combined with cisplatin could inhibit the tumor growth, induce the apoptosis, and increase ROS accumulation in ESCC cells (Supplementary Figure 3). This evidence concerns the gene SERPINE1 and esophageal squamous cell carcinoma.